Macular Measurements May Spot Visual Defects in Alzheimer's Macular Measurements May Spot Visual Defects in Alzheimer's

Changes in the retina of patients with Alzheimer's disease (AD) appear to be associated with visual dysfunction, according to Spanish researchers.Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

The identification of mutations in the amyloid precursor protein (APP) and PSEN1 and PSEN2 that cause autosomal dominantly inherited Alzheimer ’s disease (AD) and result in increased production of aggregation-prone forms of amyloid-β (Aβ) established beyond a doubt that APP processing and the production of Aβ peptides are intimately involved in the disease process and led to the proposal of and support for the amyloid cascade hypothes is for AD (1,2). Despite its strengths, the amyloid cascade hypothesis is incomplete without addressing the essential role of amyloid-associated proteins [for reviews, see (3,4)].
Source: Biological Psychiatry - Category: Psychiatry Authors: Tags: Commentary Source Type: research
Alzheimer ’s disease (AD) is characterized by the hallmark pathologies of amyloid-β (Aβ) plaques and tau tangles. Recently, many drug trials and much research have focused on preventing or removing these pathologies, especially Aβ. While some trials have been able to effect change in amyloid levels, none have succeeded in improving cognition. Although the trials may have involved patients that were too advanced for benefit with antiamyloid therapies, an inability of these drugs to protect synaptic function may have contributed to their failure.
Source: Biological Psychiatry - Category: Psychiatry Authors: Tags: Commentary Source Type: research
With the advances of modern medicine, people are living longer than ever before worldwide. Consequently, an increase in patients with dementia has become a serious social concern, with Alzheimer ’s disease (AD) being the most common form of dementia. In 2015, the World Alzheimer Report estimated that approximately 46.8 million people had AD and other types of dementia worldwide. Accordingly, the number of such patients is predicted to increase to more than 131.5 million by the year 2050. Therefore, the development of new therapeutic alternatives to control AD progression and even reverse the disease is urgently needed.
Source: Biological Psychiatry - Category: Psychiatry Authors: Tags: Commentary Source Type: research
Multisensory impairment may serve as a potential marker to help identify older adults at increased risk of developing dementia or Alzheimer disease.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Conclusions: Overall, Periventricular WMHs of grade 2 and over were seen in 19/34 patients, and in 7/24 controls (P value 0.044). Significantly higher grades of PVWMHs were seen in hypertensives as compared to nonhypertensives in the case group, and in women compared to men. In the control group, hypertension had no effect on severity of PVWMHs. Among both Diabetics and non-diabetics, no difference in PVWMHs was found between the case and control groups. DWMHs were, conversely, seen only in the control group. Overall, over a quarter of cognitively normal older persons had WM hyperintensities of grade 2 and over on MRI brai...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
BACKGROUND/OBJECTIVES: Most people with Alzheimer disease and related dementias will experience agitated and/or aggressive behaviors during the later stages of the disease. These behaviors cause significant stress for people living with dementia and their ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
In conclusion, we show here that sEVs are responsible for mediating paracrine senescence and speculate that they could be involved in inducing bystander senescence during therapy-induced senescence or aging. In fact, when compared to soluble factors, sEVs have different biophysical and biochemical properties as they have a longer lifespan than do soluble factors and they are more resistant to protease degradation. The idea that blocking sEV secretion could be a potential therapeutic approach to alleviate senescence "spreading" during chemotherapy-induced senescence or in aging tissues presents itself as a very at...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 13 July 2019Source: Journal of Herbal MedicineAuthor(s): Swati Vyas, S.L. Kothari, Sumita KachhwahaAbstractWith the rise in the ageing population in the last few decades, dementia has emerged as a serious global health issue. Alzheimer's disease (AD) is the most common type of dementia. Despite extensive drug development research, only a limited number of FDA-approved drugs are available for AD. As these drugs provide symptomatic relief only and are frequently associated with adverse effects, there remains an urgent need for developing alternative approaches to AD therapeutics. Several me...
Source: Journal of Herbal Medicine - Category: Complementary Medicine Source Type: research
“In my case, symptoms began to appear when I was only 57. In fact, the doctors believe early-onset Alzheimer’s has a strong genetic predictor, and that it may have been progressing for some years before I was diagnosed.” – Pat Summitt  Anyone who’s gone through the experience of a loved one developing Alzheimer’s disease and progressively deteriorating to a shell of their former selves knows how devastating this brain disease is for both patient and those who love and care for him or her.  Memory Performance Changes May Show Up in 20s with Family History of Alzheimer’s St...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Aging Alzheimer's Memory and Perception Alzheimer's disease Dementia Source Type: blogs
There hasn’t been much good news about Alzheimer’s lately, between the March announcement by Biogen and Esai that a promising trial of a potential drug treatment failed, and the July decision by Novartis and Amgen to stop their study of another class of therapies for the neurodegenerative disease. But in a pair of studies presented at the annual Alzheimer’s Association International Conference on July 14, researchers reported encouraging results from studies of non-drug approaches. In one, scientists led by Dr. Klodian Dhana at Rush University Medical Center in Chicago followed nearly 2,500 people for alm...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Alzheimer's Brain embargoed study Source Type: news
More News: Alzheimer's | Brain | Neurology | Neurosurgery | Opthalmology